Cervical cancer screening varies by HPV vaccination status among a National Cohort of privately insured young women in the United States 2006–2016. Issue 41 (15th October 2021)

• Record Type: Journal Article
• Authors: Ba, Djibril M.; McCall-Hosenfeld, Jennifer S.; Ssentongo, Paddy; Chinchilli, Vernon M.; Agbese, Edeanya; Liu, Guodong; Leslie, Douglas L.; Du, Ping
• Other Names: Khan. Abrar Hussain section editor.
• Is Part Of: Medicine. Volume 100:Issue 41(2021)
• Publication Date: 2021-10-15
• Subjects: cervical cancer screening -- human Papillomavirus vaccine -- private insurance -- women; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000027457
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Human papillomavirus (HPV) vaccination in young women is low. Women aged 21 to 65 years in the United States (U.S.) have not reached the Healthy People 2020 objective of 93% for cervical cancer screening. The main aim of this study was to investigate the association between HPV vaccination status and cervical cancer screening among privately insured women aged 21 to 26 years in the U.S. This was a retrospective cohort study using the IBM MarketScan database (2006–2016). The study population included 190, 982 HPV-vaccinated women and 763, 928 matched unvaccinated women. Adjusted incidence rate ratio (IRR) and the 95% confidence intervals (CIs) were obtained using the generalized estimating equations models with a Poisson distribution. Among a total of 954, 910 women included in the analysis, age (mean [SD]) was 23.3 [1.6] years. During 967, 317 person-years of follow-up, a total of 475, 702 incidents of cervical cancer screening were identified. The incidence density rates of cervical cancer screening were 461 per 1000 person-years (PY) for unvaccinated women and 787 per 1000 PY for those who received 3 doses of the HPV vaccine. After adjusting for other covariates, the IRR of cervical cancer screening was 34% higher among HPV-vaccinated women with at least one vaccine dose than unvaccinated women (adjusted IRR = 1.34, 95% CI: 1.33–1.35; P < .0001). The IRR of cervical cancer screening varied by the dose of HPV vaccination. There was evidence of a linear dose–response relationship between the number of HPV vaccine doses and cervical cancer screening ( P -trend < .0001). Compared with unvaccinated women, the IRR of cervical cancer screening were 14%, 39%, and 60% higher among those who received 1, 2, and 3 doses of the HPV vaccine, respectively. In this large retrospective cohort study of privately insured women, HPV-vaccinated women were more likely to be screened for cervical cancer compared with unvaccinated women. Abstract : Supplemental Digital Content is available in the text